Cleerly LABS vs CARTO™ 3 EP Navigation System Software V8.0 (FG-5400-00

Cleerly LABS (Tool A) is a web-based software application, offering broad accessibility and ease of use from various locations. In contrast, the CARTOu2122 3 EP Navigation System (Tool B) is an on-premise system integrated into an EP lab, which, while optimized for its specific environment, may present a higher barrier to general access and setup. Therefore, Tool A wins for its more accessible and flexible deployment model.

Cleerly LABS (Tool A) focuses on comprehensive CCTA analysis for early detection, quantification, and characterization of atherosclerosis, aiming to prevent heart attacks through personalized management. The CARTOu2122 3 EP Navigation System (Tool B) provides an AI-powered 3D cardiac mapping and navigation system crucial for diagnosing and treating complex heart rhythm disorders. Both offer significant clinical value in their respective domains, but Tool A's focus on proactive, personalized heart disease management and prevention across a broader patient population may offer a more widespread long-term impact.

Cleerly LABS (Tool A) provides transparent pricing per analysis, including a retail price and a discounted offer, allowing potential users to clearly understand the cost structure. In contrast, the CARTOu2122 3 EP Navigation System (Tool B) pricing is not publicly available and requires direct consultation, making it difficult to assess its value proposition upfront. The transparency of Tool A's pricing model gives it an advantage in this dimension.

Cleerly LABS (Tool A) is cloud-based (AWS) with explicit integration capabilities for PACS, RIS, and EHR via an on-site proxy, along with HIPAA compliance and BAA. The CARTOu2122 3 EP Navigation System (Tool B) is primarily an on-premise system with optional cloud storage for data, and while HIPAA compliant for its cloud platform, its integration details with broader hospital systems are less explicitly stated. Tool A's cloud-native architecture and clear integration pathways make it more readily adaptable for enterprise-wide deployment and data flow.

Cleerly LABS (Tool A) innovates by providing comprehensive AI-powered CCTA analysis for detailed coronary plaque assessment, moving beyond traditional stenosis evaluation to personalize heart disease risk and management, which represents a paradigm shift in diagnostics. The CARTOu2122 3 EP Navigation System (Tool B) leverages AI and deep learning for advanced 3D cardiac mapping, signal analysis, and automated anatomical creation, significantly enhancing complex electrophysiology procedures. While both are highly innovative, Tool A's approach to fundamentally changing the diagnostic paradigm for coronary artery disease offers a potentially broader and more foundational impact on cardiovascular care.

Cleerly LABS (Tool A) explicitly states its support availability as Monday through Friday from 10 am ET to 6 pm ET, with after-hours needs addressed as a first priority. While the CARTOu2122 3 EP Navigation System (Tool B) mentions instructions for use and user guides, Cleerly's explicit detailing of support hours and after-hours priority suggests a more clearly defined and structured support system.